SHENZHEN, China, Aug. 12 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - further to the Company news release of July 9, 2009 http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds today at 10:30AM EST that the Company has completed the necessary filings required to correct the ownership of its intellectual property (IP) rights.
Having performed an extensive audit and investigation on five (5) issued patents, HTDS finds that the Company should have been assigned full ownership of the patents. Filings were made today with the U.S. Patent and Trademark Office that formalize, and secure HTTD's ownership and rights to the patents. http://www.uspto.gov
In summary, The IP rights are being utilized by a fully reporting OTCBB publicly traded company. As a result of HTDS IP rights, this company has raised substantial monies in equity financing, constructed an operating plant that generates revenue, is in the process of purchasing parcels of property in various States in order to construct additional plants. It also has had numerous industrial bonds approved for several million dollars each.
The issuer for the time being has elected not to name the OTCBB publicly traded company that is utilizing its rights, however HTDS has placed the OTCBB company on formal notice. Notwithstanding, HTDS management is looking towards a mutually amicable resolution of this matter. HTDS is of the opinion that this OTCBB company got off to a great start, primarily because of these patents, which rightfully belong to HTDS. HTDS takes the position that there is no good or valid dispute that these IP rights belong to anyone else but HTDS. The following SEC filing http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=652915 dated June 2, 2000 together with today's filings with the U.S. Patent and Trademark Office http://www.uspto.gov are self explanatory and apparent on their face.
The issuer expects a "knee jerk" reaction by the OTCBB Company, including the standard form letter type denials issued by their barristers, a denouncement and a host of other panic stricken immediate type reactions. HTDS management intentions are neither to harm the OTCBB operations nor to destabilize OTCBB shareholders value. Instead, it will seek a harmonious "WIN-WIN" solution. Once the rights are finalized, HTDS is positioning itself to aggressively move the recycling industry to a higher level, with a separate recycling operating division inside HTDS; which should not disrupt HTDS' primary Bio Chem and Vaccine business. In the event the OTCBB utilizing HTDS rights is willing to cooperate, HTDS may very well have found a new partner. HTDS management is also mindful that refusal of this infringement may leave the HTDS management with no other alternative but to attorn these IP rights and to appoint an interim HTDS management to assume the recycling operations.
The management of HTDS is not ruling out any options at this point. Either way, once HTDS assumes control, the management anticipates gross revenue exceeding $250 million within two years.
Resolutions and a decision are expected shortly.
In other company news, Mr Terry Yuan CEO of HTDS said "We are delighted by the recent events taking place at HTDS. We wish to take this opportunity to advise our shareholders, and followers that some of the aforementioned revenue figures of both this release and the one of July 9, 2009 were derived directly from the OTCBB Company SEC Filings, and figures taken from OTCBB Company confidential brochures furnished to its accredited investors. We have in our possession, and we intend to file with the Pink Sheets shortly the USPTO corrective filings, the FedEx delivery and HTDS notice of infringements served upon the OTCBB directors, officers, and its auditors in the event of failed mutually acceptable resolution to the IP rights.
At HTDS and here in China we continue business as usual focusing on daily operations. Our extensive audit and investigation on these five (5) issued patents started months ago. There are many outstanding follow up matters which we intend to fully follow up with such as: CEO message from both operating subsidiaries Slavica Bio Chem in Serbia and Mellow Hope in China, our financial filings due shortly, pending legal opinion on the filed adequate disclosure, update on the slander lawsuit where HTDS is one of several beneficiaries, forward guidance, our pennies plus set targeted share price to name a few. Over the course of time we will be providing all of these updates on a timely basis including new, and pending contracts, and progresses we made so far. This is truly an exciting time to be part of the HTDS organization, and we appreciate all of our shareholders and followers sharing that joy mutually with us"
Additional details and information will be released as they become available, via regular news releases or via Pink Sheets filing service.
Safe Harbor Statement:
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved